Pharmafile Logo
Pharmafocus logo
Advanced Search

Roche

Showing 15 posts of 710 posts found.

Bayer-helmed oncology biomarker project launched

March 14, 2011
Manufacturing and Production, Research and Development AstraZeneca, Bayer, Janssen, Max Planck Institute, Merck, OncoTrack, Pfizer, Roche, biomarkers, oncology

A project to develop the next generation of oncology biomarkers has been launched in Berlin. The pharma industry and European …

News

NICE stands firm on Tarceva

March 11, 2011
Cancer, NICE, Roche, Tarceva, erlotinib

NICE has not recommended Roche’s lung cancer drug Tarceva because its effectiveness as a maintenance therapy remains unclear. NICE is …

News
Roche's Avastin (bevacizumab)

Avastin’s breast cancer use to continue in Europe

March 2, 2011
Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel

Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …

News
Roche building

Roche pulls out of vaccine alliance with Transgene

February 23, 2011
Research and Development HPV, HPV vaccine, Roche, TG4001, Transgene, cervical cancer, cervical lesions, human papilloma virus, vaccines

Roche has terminated its license agreement with Transgene for its HPV therapeutic vaccine TG4001. The vaccine is currently being tested …

News
Roche's Avastin (bevacizumab)

NICE yes for Votrient, no to Avastin

February 23, 2011
Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …

News

Roche eyes ovarian cancer expansion for Avastin

February 8, 2011
Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer

Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …

News
Roche's Avastin (bevacizumab)

Survey shows doctors support FDA Avastin decision

February 7, 2011
Sales and Marketing FDA, Roche, Sermo, avastin, bevacizumab

A survey of US doctors suggests that a majority support the FDA’s decision to take away Avastin’s licence for use …

News
Roche Severin Schwann

Roche weathers tough year and looks to pipeline for 2011

February 3, 2011
Research and Development, Sales and Marketing 2010 pharma results, BRAF protein, GDC-0449, RG3616, RG7204, Roche, avastin, pertuzumab

Roche is looking to its innovative late-stage pipeline to help it get back on track for the next financial year …

News

Diabetes success for Sanofi, disappointment for Roche

February 2, 2011
Roche, Sanofi, diabetes

The contrasting fortunes of two new diabetes became clear today, with Sanofi-Aventis lixisenatide performing well, as Roche abandoned taspoglutide.Sanofi’s lixisenatide, …

News

Tarceva set for first line treatment

January 31, 2011
Sales and Marketing Iressa, NSCLC, Roche, Tarceva

Roche’s lung cancer treatment Tarceva has been shown to help patients as a first line treatment. An independent data monitoring …

News

Bio and clinical plants feature in 2011 FOYA honours

January 25, 2011
Manufacturing and Production MedImmune, Merck & Co, Novartis, Pfizer, Roche, Shire HGT, pharma manufacturing

Three US and three European manufacturing plants have been shortlisted for the annual Facility of the Year awards, with the …

News
Roche building

Trial success for Roche’s personalised skin cancer drug

January 19, 2011
Research and Development BRAF V600, Cancer, RG7204, Roche, personalised medicine, skin cancer

A promising Roche drug has helped previously untreated patients with advanced skin cancer to live longer without their disease getting …

News

Roche finance chief steps down

January 17, 2011
Sales and Marketing Alan Hippe, Erich Hunziker, Roche, appointment, sales and marketing

Roche’s chief financial officer Erich Hunziker is to retire at the end of March after ten years with the company. …

Appointment

Novartis challenges Roche with MabThera biosimilar

January 11, 2011
Research and Development Lonza MabThera, Novartis, Roche, Teva, biosimilar, rituximab

Novartis’ generics unit Sandoz has begun mid-stage trials of a biosimilar version of Roche’s blockbuster drug MabThera. The phase II …

News
Avastin (bevacizumab) packs

Study highlights Avastin heart failure risk

January 6, 2011
Research and Development, Sales and Marketing Roche, avastin, bevacizumab, breast cancer

A new study confirms that Roche’s Avastin is linked to a small but significant increased risk of heart failure in …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026